Company intelligence / Profile preview
Leapfrog Bio
San Mateo, California, USAleapfrog.bio ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Leapfrog Bio’s lead candidate LFB190 targets solid tumors with EP300 loss-of-function mutations using a BET inhibitor. The compound is Phase 2-ready for lung, bladder, and colon cancers. Their platform has shown strong retrospective validation in real-world data analyses and preclinical models. Clinical trials are expected to begin in 2025 for LFB190; additional candidates are advancing toward the clinic.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Leapfrog works with pharmaceutical/biotech companies to retarget shelved product candidates for new oncology indications but no specific partners have been publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Leapfrog Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leapfrog Bio.